-
FDA Approves Cobenfy as Novel Schizophrenia Treatment with First-in-Decades Mechanism
•
The U.S. Food and Drug Administration (FDA) has granted official approval to Cobenfy (KarXT, xanomeline and trospium chloride) as an oral treatment for schizophrenia, marking it as the first therapy with a novel mechanism of action in this indication in several decades within the U.S. KarXT, an oral M1/M4 type…
-
BMS to Acquire Karuna Therapeutics for $14 Billion, Expanding Psychosis Treatment Portfolio
•
Bristol Myers Squibb (BMS; NYSE: BMY), a leading US pharmaceutical company, has announced its intention to acquire Karuna Therapeutics, Inc. (NASDAQ: KRTX) for a total consideration of USD 14 billion. This acquisition will bolster BMS’s product pipeline with the inclusion of the antipsychotic drug KarXT (xanomeline-trospium), which is currently awaiting…
